230 related articles for article (PubMed ID: 23855668)
1. Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma.
Abbhi V; Piplani P
Curr Drug Deliv; 2016; 13(6):818-29. PubMed ID: 23855668
[TBL] [Abstract][Full Text] [Related]
2. Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility.
Abbhi V; Piplani P
Curr Med Chem; 2020; 27(14):2222-2256. PubMed ID: 30378487
[TBL] [Abstract][Full Text] [Related]
3. Rho-kinase inhibitors in the management of glaucoma.
Berrino E; Supuran CT
Expert Opin Ther Pat; 2019 Oct; 29(10):817-827. PubMed ID: 31573364
[No Abstract] [Full Text] [Related]
4. A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
Hsu CR; Chen YH; Liu CP; Chen CH; Huang KK; Huang JW; Lin MN; Lin CL; Chen WR; Hsu YL; Lee TC; Chou SH; Tu CM; Hwang CS; Huang YC; Lu DW
Invest Ophthalmol Vis Sci; 2019 Feb; 60(2):624-633. PubMed ID: 30735565
[TBL] [Abstract][Full Text] [Related]
5. Rho/Rho-associated kinase pathway in glaucoma (Review).
Wang J; Liu X; Zhong Y
Int J Oncol; 2013 Nov; 43(5):1357-67. PubMed ID: 24042317
[TBL] [Abstract][Full Text] [Related]
6. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.
Rao PV; Pattabiraman PP; Kopczynski C
Exp Eye Res; 2017 May; 158():23-32. PubMed ID: 27593914
[TBL] [Abstract][Full Text] [Related]
7. Rho-associated kinase inhibitors: a novel glaucoma therapy.
Inoue T; Tanihara H
Prog Retin Eye Res; 2013 Nov; 37():1-12. PubMed ID: 23770081
[TBL] [Abstract][Full Text] [Related]
8. Rho kinase inhibitors for glaucoma treatment - Review.
Germano RA; Finzi S; Challa P; Susanna Junior R
Arq Bras Oftalmol; 2015; 78(6):388-91. PubMed ID: 26677046
[TBL] [Abstract][Full Text] [Related]
9. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.
Inoue T; Tanihara H
Expert Opin Pharmacother; 2017 Oct; 18(15):1669-1673. PubMed ID: 28893104
[TBL] [Abstract][Full Text] [Related]
10. Rho-kinase inhibitors offer a new approach in the treatment of glaucoma.
Challa P; Arnold JJ
Expert Opin Investig Drugs; 2014 Jan; 23(1):81-95. PubMed ID: 24094075
[TBL] [Abstract][Full Text] [Related]
11. The Application of Rho Kinase Inhibitors in the Management of Glaucoma.
Liu LC; Chen YH; Lu DW
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891764
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel inhibitors for the treatment of glaucoma.
Cholkar K; Trinh HM; Pal D; Mitra AK
Expert Opin Drug Discov; 2015 Mar; 10(3):293-313. PubMed ID: 25575654
[TBL] [Abstract][Full Text] [Related]
13. Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment.
Schehlein EM; Robin AL
Drugs; 2019 Jul; 79(10):1031-1036. PubMed ID: 31134520
[TBL] [Abstract][Full Text] [Related]
14. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
Honjo M; Tanihara H
Jpn J Ophthalmol; 2018 Mar; 62(2):109-126. PubMed ID: 29445943
[TBL] [Abstract][Full Text] [Related]
15. Potential role of Rho-associated protein kinase inhibitors for glaucoma treatment.
Colligris B; Crooke A; Huete F; Pintor J
Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):89-98. PubMed ID: 22533522
[TBL] [Abstract][Full Text] [Related]
16. Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.
Bonardi A; Supuran CT
Expert Opin Ther Pat; 2019 Oct; 29(10):753-759. PubMed ID: 31438732
[No Abstract] [Full Text] [Related]
17. Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations.
Andrés-Guerrero V; García-Feijoo J; Konstas AG
Adv Ther; 2017 May; 34(5):1049-1069. PubMed ID: 28349508
[TBL] [Abstract][Full Text] [Related]
18. Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma.
Wu J; Wei J; Chen H; Dang Y; Lei F
Curr Drug Targets; 2024; 25(2):94-107. PubMed ID: 38155465
[TBL] [Abstract][Full Text] [Related]
19. Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
Kopczynski CC; Heah T
Drugs Today (Barc); 2018 Aug; 54(8):467-478. PubMed ID: 30209441
[TBL] [Abstract][Full Text] [Related]
20. Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury.
Shaw PX; Sang A; Wang Y; Ho D; Douglas C; Dia L; Goldberg JL
Exp Eye Res; 2017 May; 158():33-42. PubMed ID: 27443501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
